【瞩目】石药集团吸入剂大爆发,超200亿市场再掀波澜

米内网
Mar 10

精彩内容3月5日,石药集团发布公告,集团开发的茚达特罗莫米松吸入粉雾剂获批在中国开展临床试验。米内网数据显示,吸入剂(化+中+生)在近年中国三大终端六大市场均保持200亿元以上销售规模,2025年Q1-Q3同比略有下滑,呼吸系统用药(化+生)是TOP1大类。3月6日,集团开发的化药1类新药SYH2059吸入粉雾剂获美国FDA批准,可以在美国开展临床试验。茚达特罗莫米松吸入粉雾剂用于成人和12岁及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10